Skip to content


Journal for ImmunoTherapy of Cancer

Open Access

Autologous dendritic cell immunotherapy (DCVAC/PCa) added to docetaxel chemotherapy in a Phase III trial (viable) in men with advanced (mCRPC) prostate cancer

  • Tomasz M Beer1,
  • Nicholas Vogelzang2,
  • Jiřina Bartůňková3,
  • Kurt Miller4,
  • William Oh5,
  • Stephane Oudard6,
  • Hardev Pandha7,
  • A Oliver Sartor8,
  • Radek Špíšek3,
  • Timothy O Toole9,
  • Niels G Borgstein9 and
  • Winald R Gerritsen10
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P164

Published: 4 November 2015


Prostate cancer (PCa) is the second most common cancer, and the fifth leading cause of cancer related death among men worldwide. Immunotherapy designed to induce tumor cell specific immune responses capable of destroying tumor cells has emerged as a promising treatment modality in solid malignant tumors. Clinical and preclinical trials have shown that docetaxel chemotherapy can be combined with DCVAC/PCa immunotherapy without impairing the immune response, while Kaplan-Meier analyses showed that patients had a lower risk of death compared with both MSKCC (Hazard Ratio 0.26, 95% CI: 0.13–0.51) and Halabi (Hazard Ratio 0.33, 95% CI: 0.17–0.63) predictions[1].


VIABLE is a randomized, double-blind, placebo-controlled, parallel-group, Phase III study to evaluate, in patients with mCRPC eligible for first-line docetaxel chemotherapy, the efficacy and safety of docetaxel chemotherapy plus DCVAC/PCa (active cellular immunotherapy based on activated dendritic cells) versus docetaxel chemotherapy plus placebo. The study was initiated in May 2014 and plans to enroll almost 1200 patients at approximately 230 sites globally. Eligible patients are required to present with metastatic castrate-resistant PCa defined by both the presence and progression of the disease, maintenance of a castrate state (less than 50 ng/dl), ECOG score 0-2, and adequate hematologic, hepatic and renal functions. All patients will receive standard of care docetaxel plus prednisone, and will be randomized 2:1 to DCVAC/PCa or placebo. Patients will be stratified by region, previous therapy and ECOG status. The primary endpoint is overall survival (OS). Assuming proportional hazards, a two-tailed level of significance of 0.05 and 80% power will be applied. Additionally this design assumes an exponential survival distribution to detect a HR = 0.792 in favor of the DCVAC/PCA group. Registration number NCT02111577, EudraCT number 2012-002814-38.

Trial registration identifier NCT02111577. EudraCT number 2012-002814-38.

Authors’ Affiliations

Oregon Health & Science University, OHSU Knight Cancer Institute, Portland, USA
US Oncology Research, Comprehensive Cancer Centers, Las Vegas, USA
University Hospital Motol, Prague, Czech Republic and SOTIO a.s., Prague, Czech Republic
Charité University Medicine Berlin, Berlin, Germany
Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
Georges Pompidou European Hospital, Paris, France
University of Surrey, Guildford, UK
Tulane Cancer Center, New Orleans, USA
Sotio, LLC, Boston, USA
Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands


  1. Podrazil M, Horvath R, Becht E, et al: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015, May 29 [epub ahead of print]Google Scholar


© Beer et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.